Peresolimab, identified by the CAS number 2411580-63-5, represents a promising antibody targeting IL-12 , a key mediator in the development of inflammatory diseases . This treatment compound functions as a selective antagonist of the IL-12/IL-23 unit, demonstrating efficacy in human trials . Pre-

Latikafusp represents a unique therapeutic approach for managing specific tumors, particularly those involving altered anaplastic lymphoma kinase proteins. This compound functions as an repressor of truncated anaplastic lymphoma kinase structures, demonstrating potential in preclinical studies an